Core Viewpoint - Southbound funds have reduced their holdings in Hai Ji Ya Medical (06078.HK) by 460,200 shares on February 2, with a total net reduction of 1,540,400 shares over the past five trading days and 6,519,200 shares over the past twenty trading days [1] Group 1: Southbound Fund Activity - Southbound funds have decreased their holdings in Hai Ji Ya Medical for 4 out of the last 5 trading days, totaling a net reduction of 1,540,400 shares [1] - Over the last 20 trading days, southbound funds have reduced their holdings on 15 days, with a cumulative net reduction of 6,519,200 shares [1] - As of now, southbound funds hold 202 million shares of Hai Ji Ya Medical, representing 32.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Hai Ji Ya Medical Holdings Limited is primarily an investment holding company that provides medical services [1] - The company operates through two business segments: the hospital business segment focuses on comprehensive cancer diagnosis and treatment services, including radiation therapy, chemotherapy, surgery, and targeted therapy [1] - The other business segment is involved in various other operations, with the company primarily conducting its business in the domestic market [1]

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 2.23% to 26,775.57 points, and the Hang Seng Tech Index dropping by 3.36% to 5,526.31 points [1] - Major technology stocks saw significant losses, including Alibaba down 3.49%, Tencent down 1.24%, and JD.com down 1.69% [1] - Gold and silver prices fell sharply, with Shandong Gold and Chifeng Gold both dropping over 12% [1] Company Earnings Forecasts - Haiprime (09989.HK) expects a net profit of 284 million to 377 million yuan for 2025, a decrease of 41.71% to 56.09% year-on-year [2] - Datang Power (00991.HK) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, an increase of about 51% to 73% year-on-year [6] - Longhua Automobile (02333.HK) projects total revenue of 222.79 billion yuan for 2025, a year-on-year growth of 10.19% [4] - CICC (03908.HK) forecasts a net profit of 8.542 billion to 10.535 billion yuan for 2025, an increase of 50% to 85% year-on-year [5] Company Warnings - Kaisa New Energy (01108.HK) issued a profit warning, expecting a net loss increase of approximately 90.07 million to 290 million yuan for 2025 [7] - Xinyi Alloy (00505.HK) also issued a profit warning, anticipating a 50% decrease in profit attributable to equity shareholders for 2025 [8] - Fudan Zhangjiang (01349.HK) expects a net loss of approximately 120 million to 180 million yuan for 2025 [9] Strategic Developments - Innovation Intelligence (02121.HK) signed a strategic cooperation agreement with Shanghai Jiao Tong University Hainan Research Institute [11] - Zhonghui Biotech-B (02627.HK) received approval from the National Medical Products Administration for its trivalent influenza virus subunit vaccine [12]

Group 1 - Hai Jiaya Medical (06078.HK) saw a rise of over 4%, with a current increase of 4.13%, trading at HKD 13.35 [2] - The trading volume reached HKD 62.3713 million [2]

Core Viewpoint - Haijia Medical (06078) anticipates a decline in revenue and net profit for 2025, primarily due to goodwill impairment and increased operational costs [1][4] Financial Projections - Expected revenue for 2025 is approximately RMB 4.0–4.5 billion, representing a year-on-year decrease of about 9% to 10% [1][4] - Projected net profit is around RMB 140–200 million, reflecting a year-on-year decline of approximately 66% to 76% [1][4] - Adjusted net profit is estimated to be between RMB 450–490 million, down about 19% to 25% year-on-year [1][4] - Cash generated from operating activities is expected to be around RMB 940–1,000 million, showing an increase of approximately 33% to 41% year-on-year [1][4] Factors Influencing Financial Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation for newly opened hospitals [1][4] - The net profit decrease is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1][4] - The company has conducted a careful assessment of its operational and financial performance, as well as future business prospects, to determine the necessity and amount of the impairment and provision [1][4]

公告称，收入、净利润及非国际财务报告准则经调整净利润下降主要是由于行业及宏观经济影响，以及 集团新开业医院开办费及折旧摊销增加的影响。集团截至2025年12月31日止年度的净利润下降除了上述 因素外，还主要由于Etern Group Ltd.的商誉减值拨备。于厘定有关减值及拨备的必要性及金额时，公司 已仔细评估集团的营运及财务表现以及其业务的未来前景。实际减值及拨备金额仍须待公司进一步评估 后方可作实。 智通财经APP获悉，海吉亚医疗(06078)涨超4%，截至发稿，涨4.13%，报13.35港元，成交额6237.13万 港元。 消息面上，海吉亚医疗公布，预期2025年的收入约为人民币40.0–40.5亿元，同比下降约9%至10%；净 利润约为人民币1.4–2.0亿元，同比下降约66%至76%(主要受商誉减值影响)；经调整净利润约为人民币 4.5–4.9亿元，同比下降约19%至25%；经营活动所得现金净额约为人民币9.4–10.0亿元，同比增加约33% 至41%。 ...

Core Viewpoint - Haijia Medical (06078) shares rose over 4%, currently up 4.13% at HKD 13.35, with a trading volume of HKD 62.37 million [1] Financial Projections - The company expects revenue for 2025 to be approximately RMB 4.0–4.05 billion, representing a year-on-year decline of about 9% to 10% [1] - Net profit is projected to be around RMB 140–200 million, reflecting a year-on-year decrease of approximately 66% to 76%, primarily due to goodwill impairment [1] - Adjusted net profit is anticipated to be between RMB 450–490 million, indicating a year-on-year decline of about 19% to 25% [1] - Cash generated from operating activities is expected to be around RMB 940–1,000 million, showing a year-on-year increase of approximately 33% to 41% [1] Factors Influencing Financial Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation for newly opened hospitals [1] - The decrease in net profit for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, along with future business prospects, to determine the necessity and amount of the impairment and provision [1]

Core Viewpoint - Haijia Medical announced that it expects to achieve a quarter-on-quarter increase in revenue and patient visits in the second half of 2025, indicating a marginal improvement in operational performance [1] Financial Performance - The company's operating cash flow for the year is projected to be between RMB 940 million and RMB 1 billion, representing a year-on-year growth of approximately 33% to 41% [1] - The net bank debt is expected to decrease by RMB 340 million by the end of 2025, with capital expenditures anticipated to decline by 16% to 24% year-on-year [1] Operational Quality - The company is solidifying its operational quality, with ongoing construction projects nearing completion, which may further reduce future capital expenditure [1] - The apparent net profit has decreased primarily due to goodwill impairment, which is a one-time accounting adjustment and does not involve actual cash outflow [1]

Core Viewpoint - Haijia Medical announced that it expects to achieve a quarter-on-quarter increase in revenue and patient visits in the second half of 2025, indicating marginal improvement in operations [1] Financial Performance - The company's operating cash flow for the year is projected to be between RMB 940 million and RMB 1 billion, representing a year-on-year growth of approximately 33% to 41% [1] - The net bank debt is expected to decrease by RMB 340 million by the end of 2025, while capital expenditures are anticipated to decline by 16% to 24% year-on-year [1] Operational Quality - The company is solidifying its operational quality, with ongoing construction projects nearing completion, which is likely to further reduce future capital expenditure [1] - The apparent net profit has decreased primarily due to goodwill impairment, which is a one-time accounting adjustment and does not involve actual cash outflow [1]

Company News - Great Wall Motors (02333.HK) expects a total revenue of RMB 222.79 billion in 2025, representing a year-on-year increase of 10.19%. However, net profit is projected to decline by 21.71% to RMB 9.912 billion due to increased investments in new user channels and marketing for new models and technologies [2] - China Southern Airlines (01055.HK) anticipates turning a profit in 2025, with net profit expected to be between RMB 800 million and RMB 1 billion [2] - CICC (03908.HK) forecasts a net profit of RMB 8.542 billion to RMB 10.535 billion in 2025, reflecting a year-on-year increase of 50% to 85% [3] - Datang Power (00991.HK) projects a net profit of approximately RMB 6.8 billion to RMB 7.8 billion in 2025, indicating a year-on-year increase of about 51% to 73% [4] - Rongchang Bio (09995.HK) expects 2025 revenue of approximately RMB 3.25 billion, a year-on-year increase of about 89%, and a net profit of around RMB 716 million, achieving profitability [4] - Haijia Medical (06078.HK) anticipates revenue of approximately RMB 4.0 billion to RMB 4.05 billion in 2025, a year-on-year decrease of about 9% to 10%, with net profit expected to decline by 66% to 76% to around RMB 140 million to RMB 200 million [4] - Junshi Biosciences (01877.HK) expects 2025 revenue of around RMB 2.5 billion, a year-on-year increase of approximately 28.32%, with a net loss of about RMB 873 million, a reduction of 31.85% compared to the previous year [4] - Kaisa New Energy (01108.HK) issued a profit warning, expecting a year-on-year increase in net loss of approximately RMB 90.07 million to RMB 290 million [4] - Xingye Alloy (00505.HK) issued a profit warning, anticipating a year-on-year decrease in profit attributable to equity shareholders of about 50% [4] - Fudan Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of approximately RMB 120 million to RMB 180 million in 2025 [4] - Chenming Paper (01812.HK) issued a profit warning, expecting a net loss of RMB 8.2 billion to RMB 8.8 billion, a significant increase compared to the previous year [5] - Tianqi Lithium (09696.HK) has commenced production of the first batch of standard chemical-grade lithium concentrate products from its third-phase expansion project [6] Financing and Buyback Activities - Xiaomi Group-W (01810.HK) repurchased approximately 4.2 million shares for about HKD 150 million, with repurchase prices ranging from HKD 35.13 to HKD 42.50 [10] - Vitasoy International (00345.HK) repurchased shares worth HKD 24.37 million, acquiring 3.492 million shares at prices between HKD 6.9 and HKD 7 [11] - Yujian Xiaomian (02408.HK) plans to repurchase up to HKD 100 million of H-shares [12] - Nanshan Aluminum International (02610.HK) completed a placement of 31 million shares, raising approximately HKD 1.987 billion [12]

Core Viewpoint - Haijia Medical (06078) anticipates a decline in revenue and net profit for 2025, primarily due to goodwill impairment and increased operational costs [1] Financial Projections - The company expects revenue for 2025 to be approximately RMB 4.0–4.5 billion, representing a year-on-year decrease of about 9% to 10% [1] - Net profit is projected to be around RMB 140–200 million, reflecting a significant year-on-year decline of approximately 66% to 76% [1] - Adjusted net profit is estimated at RMB 450–490 million, indicating a year-on-year decrease of about 19% to 25% [1] - Cash generated from operating activities is expected to be between RMB 940–1,000 million, showing a year-on-year increase of approximately 33% to 41% [1] Factors Influencing Performance - The decline in revenue, net profit, and adjusted net profit is attributed to industry and macroeconomic impacts, as well as increased startup costs and depreciation expenses from newly opened hospitals [1] - The anticipated drop in net profit for the year ending December 31, 2025, is also significantly influenced by the goodwill impairment provision related to Etern Group Ltd. [1] - The company has conducted a careful assessment of its operational and financial performance, along with future business prospects, to determine the necessity and amount of the impairment and provision [1]